- |||||||||| sevuparin (DF-02) / Modus Therap, Mahidol Oxford Tropical Medicine Research Unit
Preclinical, Journal: Sevuparin strongly reduces hepcidin expression in cells, mice, and healthy human volunteers. (Pubmed Central) - Dec 2, 2024
Moreover, sevuparin was able to reduce hepcidin upregulation in a mouse model of acute inflammation induced by LPS, also showing an amelioration of the inflammatory markers. Combined with its excellent safety profile, these data suggest a role for sevuparin in treating high-hepcidin disorders.
- |||||||||| sevuparin (DF-02) / Modus Therap, Mahidol Oxford Tropical Medicine Research Unit, Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin
The Heparinoid Sevuparin Improves Anemia and Kidney Status in a Mouse Model of Chronic Kidney Disease (SDCC - Halls G-H) - Nov 3, 2023 - Abstract #ASH2023ASH_3390;
Our data in this mouse CKD model add new insights to the role of hepcidin in the development of CKD anemia over time. Furthermore, the results are promising and support further mechanistic and clinical studies to elucidate the therapeutic role for sevuparin as a treatment in anemia of inflammatory and/or chronic diseases in monotherapy or in combination with EPO and to explore its role in kidney protection.
- |||||||||| Biologic Assessment of RBC Biology and Neutrophil Activation: Correlation with Sickle Cell Disease Activity (SDCC - Halls G-H) - Nov 3, 2023 - Abstract #ASH2023ASH_1521;
On the other hand, higher HbF levels were associated with lower admission rates for VOE and a trend toward lower levels of neutrophil activation. This suggests that higher HbF, beyond its ability to reduce sickling, also alters other biological characteristics of SS RBCs and is accompanied by reduction in the inflammatory nature of SCD, thereby contributing to a decrease in VOE frequency.
- |||||||||| Review, Journal: Recent developments in antimalarial drug discovery. (Pubmed Central) - Jun 2, 2023
Although these adjuvants have no antiplasmodial activity, they can help to alleviate the effects which result from plasmodium invasion such as cytoadherence. The list of new antimalarial drugs under development is long, including the out of ordinary new drugs MMV048, CDRI-97/78 and INE963 from South Africa, India and Novartis, respectively.
- |||||||||| sevuparin (DF-02) / Modus Therap, Mahidol Oxford Tropical Medicine Research Unit
Clinical, P2 data, Journal: Sevuparin for the treatment of acute pain crisis in patients with sickle cell disease: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. (Pubmed Central) - May 4, 2021
P2
No abstract available This result, as well as the results seen in other clinical studies of inhibitors of adhesion in sickle cell disease, suggest that selectin-mediated adhesion might be important in the initiation, but not maintenance of vaso-occlusion, indicating that strategies to treat vaso-occlusive crises differ from strategies to prevent this complication.
- |||||||||| sevuparin (DF-02) / Modus Therap, Mahidol Oxford Tropical Medicine Research Unit
Journal: Heparinoid sevuparin inhibits Streptococcus-induced vascular leak through neutralizing neutrophil-derived proteins. (Pubmed Central) - May 28, 2020
By mass spectrometry of neutrophil secretion, we identify proteins, including serprocidins, S100 proteins, and histone H4, that interact with sevuparin and that are responsible for the disruptive effect on endothelial integrity. Collectively, our results demonstrate the critical role of neutrophil-derived proteins in vascular hyperpermeability caused by GAS and suggest sevuparin as a potential therapeutic in acute neutrophilic inflammation.-Rasmuson, J., Kenne, E., Wahlgren, M., Soehnlein, O., Lindbom, L. Heparinoid sevuparin inhibits Streptococcus-induced vascular leak through neutralizing neutrophil-derived proteins.
- |||||||||| sevuparin (DF-02) / Modus Therap, Mahidol Oxford Tropical Medicine Research Unit
Journal: Sevuparin blocks sickle blood cell adhesion and sickle-leucocyte rolling on immobilized L-selectin in a dose dependent manner. (Pubmed Central) - Jan 1, 2020
Collectively, our results demonstrate the critical role of neutrophil-derived proteins in vascular hyperpermeability caused by GAS and suggest sevuparin as a potential therapeutic in acute neutrophilic inflammation.-Rasmuson, J., Kenne, E., Wahlgren, M., Soehnlein, O., Lindbom, L. Heparinoid sevuparin inhibits Streptococcus-induced vascular leak through neutralizing neutrophil-derived proteins. No abstract available
- |||||||||| sevuparin (DF-02) / Modus Therap, Mahidol Oxford Tropical Medicine Research Unit
Trial completion: Sevuparin Infusion for the Management of Acute VOC in Subjects With SCD (clinicaltrials.gov) - Jul 15, 2019
P2, N=147, Completed,
It is possible that once full-blown, an acute VOC cannot be limited by sevuparin’s mode of action (MoA) . Recruiting --> Completed
- |||||||||| Journal: Drugs in Development for Malaria. (Pubmed Central) - Mar 29, 2019
Tafenoquine is under review by stringent regulatory authorities for approval as a single-dose treatment for Plasmodium vivax relapse prevention...This fact, coupled with the repeated loss of antimalarials to resistance, indicates that new antimalarials will be needed for years to come. Failure of the artemisinin-based combinations in Southeast Asia has stimulated a reappraisal of current approaches to combination therapy for malaria with incorporation of three or more drugs in a single treatment under consideration.
- |||||||||| sevuparin (DF-02) / Modus Therap, Mahidol Oxford Tropical Medicine Research Unit
Trial completion date, Trial primary completion date: Sevuparin Infusion for the Management of Acute VOC in Subjects With SCD (clinicaltrials.gov) - Nov 27, 2018
P2, N=133, Recruiting,
Failure of the artemisinin-based combinations in Southeast Asia has stimulated a reappraisal of current approaches to combination therapy for malaria with incorporation of three or more drugs in a single treatment under consideration. Trial completion date: Oct 2018 --> Mar 2019 | Trial primary completion date: Oct 2018 --> Mar 2019
- |||||||||| sevuparin (DF-02) / Modus Therap, Mahidol Oxford Tropical Medicine Research Unit
Trial completion date, Trial primary completion date: Sevuparin Infusion for the Management of Acute VOC in Subjects With SCD (clinicaltrials.gov) - Mar 16, 2018
P2, N=133, Recruiting,
Trial completion date: Oct 2018 --> Mar 2019 | Trial primary completion date: Oct 2018 --> Mar 2019 Trial completion date: Dec 2017 --> Oct 2018 | Trial primary completion date: Dec 2017 --> Oct 2018
- |||||||||| sevuparin (DF-02) / Modus Therap, Mahidol Oxford Tropical Medicine Research Unit
Enrollment change, Trial primary completion date: Sevuparin Infusion for the Management of Acute VOC in Subjects With SCD (clinicaltrials.gov) - Apr 6, 2017
P2, N=133, Recruiting,
Trial completion date: Dec 2017 --> Oct 2018 | Trial primary completion date: Dec 2017 --> Oct 2018 N=77 --> 133 | Trial primary completion date: Dec 2016 --> Dec 2017
- |||||||||| sevuparin (DF-02) / Modus Therap, Mahidol Oxford Tropical Medicine Research Unit
Trial primary completion date: Sevuparin Infusion for the Management of Acute VOC in Subjects With SCD (clinicaltrials.gov) - Feb 17, 2016
P2, N=77, Recruiting,
N=77 --> 133 | Trial primary completion date: Dec 2016 --> Dec 2017 Trial primary completion date: Mar 2016 --> Dec 2016
|
